ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
122.098,09
-0,50%
S&P 500
5.277,51
0,80%
US Dollar vs BRL
5,2463
0,01%
Bitcoin
67.754,77
0,40%
Brent Oil
81,295
0,00%
Registration Strip Icon for pro Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Sarepta Therapeutics Inc New (SRPT)

  7. Sarepta Therapeutics Inc New (SRPT) Notícias

SRPT

Sarepta Therapeutics (SRPT)

Sarepta Therapeutics Inc New
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:SRPT
DataHoraFonteTítuloCódigoCompanhia
31/05/202418:45Business WireSarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:SRPTSarepta Therapeutics Inc New
29/05/202418:48PR Newswire (US)Sarepta Therapeutics Set to Join S&P MidCap 400NASDAQ:SRPTSarepta Therapeutics Inc New
06/05/202421:09Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SRPTSarepta Therapeutics Inc New
06/05/202421:00Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:SRPTSarepta Therapeutics Inc New
03/05/202411:07Business WireGene Therapy Pioneer Jerry R. Mendell, M.D., Named to Inaugural TIME100 Health List of the 100 Most Influential People in Global HealthNASDAQ:SRPTSarepta Therapeutics Inc New
01/05/202417:05Business WireSarepta Therapeutics Announces First Quarter 2024 Financial Results and Recent Corporate DevelopmentsNASDAQ:SRPTSarepta Therapeutics Inc New
24/04/202409:30Business WireSarepta Therapeutics to Announce First Quarter 2024 Financial ResultsNASDAQ:SRPTSarepta Therapeutics Inc New
08/03/202419:38Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:SRPTSarepta Therapeutics Inc New
04/03/202410:30Business WireSarepta Therapeutics to Present at Upcoming Investor ConferencesNASDAQ:SRPTSarepta Therapeutics Inc New
29/02/202411:00Business WireSarepta Therapeutics Announces Call for Applications for the 7th Annual Route 79, The Duchenne Scholarship ProgramNASDAQ:SRPTSarepta Therapeutics Inc New
28/02/202418:05Business WireSarepta Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Recent Corporate DevelopmentsNASDAQ:SRPTSarepta Therapeutics Inc New
21/02/202410:30Business WireSarepta Therapeutics to Announce Fourth Quarter and Full-Year 2023 Financial ResultsNASDAQ:SRPTSarepta Therapeutics Inc New
16/02/202409:00Business WireSarepta Therapeutics Announces U.S. FDA Acceptance of an Efficacy Supplement to Expand the ELEVIDYS IndicationNASDAQ:SRPTSarepta Therapeutics Inc New
13/02/202415:34Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:SRPTSarepta Therapeutics Inc New
09/02/202420:05Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:SRPTSarepta Therapeutics Inc New
29/01/202409:00Business WireSarepta Therapeutics Announces Positive Data from Part B of MOMENTUM, a Phase 2 Study of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 51NASDAQ:SRPTSarepta Therapeutics Inc New
16/01/202411:02Business WireSarepta Therapeutics Initiates Screening in EMERGENE, a Phase 3 Clinical Study of SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4NASDAQ:SRPTSarepta Therapeutics Inc New
08/01/202414:08Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SRPTSarepta Therapeutics Inc New
08/01/202413:55Business WireSarepta Therapeutics Reports Preliminary* Fourth Quarter and Full-Year 2023 Net Product RevenueNASDAQ:SRPTSarepta Therapeutics Inc New
02/01/202410:30Business WireSarepta Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:SRPTSarepta Therapeutics Inc New
22/12/202310:00Business WireSarepta Therapeutics Submits Efficacy Supplement to Expand the ELEVIDYS Label to include Duchenne Muscular Dystrophy Patients without Restriction to Age or Ambulatory StatusNASDAQ:SRPTSarepta Therapeutics Inc New
02/11/202309:30Business WireSarepta Therapeutics to Present at the UBS Biopharma ConferenceNASDAQ:SRPTSarepta Therapeutics Inc New
01/11/202317:05Business WireSarepta Therapeutics Announces Third Quarter 2023 Financial Results and Recent Corporate DevelopmentsNASDAQ:SRPTSarepta Therapeutics Inc New
01/11/202317:01Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SRPTSarepta Therapeutics Inc New
31/10/202318:30KR Market News연준 결정 앞두고 뉴욕 증시 상승; 투자자들은 실적 주목NASDAQ:SRPTSarepta Therapeutics Inc New
30/10/202318:17Dow Jones NewsSarepta Therapeutics to Request Expansion of Elevidys to All Age Groups Following Study ResultsNASDAQ:SRPTSarepta Therapeutics Inc New
30/10/202317:01Business WireSarepta Therapeutics Announces Topline Results from EMBARK, a Global Pivotal Study of ELEVIDYS Gene Therapy for Duchenne Muscular DystrophyNASDAQ:SRPTSarepta Therapeutics Inc New
25/10/202309:30Business WireSarepta Therapeutics to Announce Third Quarter 2023 Financial ResultsNASDAQ:SRPTSarepta Therapeutics Inc New
07/09/202310:00Business WireSarepta Therapeutics Announces Recipients of the 6th Annual Route 79, The Duchenne Scholarship Program, for the 2023-2024 Academic YearNASDAQ:SRPTSarepta Therapeutics Inc New
05/09/202309:30Business WireSarepta Therapeutics to Present at the Morgan Stanley 21st Annual Global Healthcare ConferenceNASDAQ:SRPTSarepta Therapeutics Inc New
 Apresentando as notícias mais relevantes sobre:NASDAQ:SRPT

Seu Histórico Recente

USOTC
FGWLF
Flughafen Wien (PK)
NASDAQ
MURFU
Murphy Canyon Acquisition
NASDAQ
FAUAX
Franklin Aggressive Grow...
EU
P787S
P787S
BOV
BBASJ437
BBASJ437 Ex:21,34
BIT
Q00556
Leonteq Securities
BIT
F16666
Vontobel Financial Produ...
BIT
UC566G
Unicredit Bank
USOTC
RTMNF
Reitmans Cda (PK)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados